Lifecore Biomedical Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Lifecore Biomedical şirketinin kazançlarının yıllık 40.1% oranında düşmesi, yıllık gelirinin ise yıllık 7.5% oranında artması bekleniyor. EPS'nin yıllık 38.4% oranında düşüşmesi bekleniyor.

Anahtar bilgiler

-40.1%

Kazanç büyüme oranı

-38.4%

EPS büyüme oranı

Life Sciences kazanç büyümesi	26.3%
Gelir büyüme oranı	7.5%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	15 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

DB:LDE - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
5/31/2027	154	-22	-4	N/A	3
5/31/2026	139	-24	-10	N/A	3
5/31/2025	129	-31	-21	N/A	3
8/25/2024	128	6	-9	7	N/A
5/26/2024	128	9	-18	0	N/A
2/25/2024	122	-21	-34	-11	N/A
11/26/2023	112	-47	-45	-21	N/A
8/27/2023	104	-70	-48	-25	N/A
5/28/2023	103	-64	-39	-17	N/A
2/26/2023	93	-31	-41	-16	N/A
11/27/2022	104	-27	-46	-22	N/A
8/28/2022	93	-15	-50	-25	N/A
5/29/2022	111	-15	-53	-23	N/A
2/27/2022	135	-12	-49	-18	N/A
11/28/2021	142	-7	-37	-8	N/A
8/29/2021	78	-6	-28	-1	N/A
5/30/2021	101	-23	-9	16	N/A
2/28/2021	283	-24	-18	-2	N/A
11/29/2020	391	-34	-2	16	N/A
8/30/2020	587	-44	-16	5	N/A
5/31/2020	160	-22	-44	-17	N/A
2/23/2020	587	-23	-39	-6	N/A
11/24/2019	590	-10	-46	-4	N/A
8/25/2019	572	-3	-32	8	N/A
5/26/2019	558	2	-29	16	N/A
2/24/2019	546	8	-29	17	N/A
11/25/2018	535	23	-24	18	N/A
8/26/2018	533	24	-24	19	N/A
5/27/2018	524	26	N/A	20	N/A
2/25/2018	448	21	N/A	27	N/A
11/26/2017	440	8	N/A	31	N/A
8/27/2017	453	9	N/A	27	N/A
5/28/2017	470	10	N/A	30	N/A
2/26/2017	540	13	N/A	39	N/A
11/27/2016	534	-12	N/A	25	N/A
8/28/2016	538	-11	N/A	30	N/A
5/29/2016	477	-12	N/A	21	N/A
2/28/2016	540	-12	N/A	19	N/A
11/29/2015	549	13	N/A	25	N/A
8/30/2015	541	14	N/A	20	N/A
5/31/2015	539	14	N/A	27	N/A
3/1/2015	526	14	N/A	21	N/A
11/30/2014	514	17	N/A	20	N/A
8/31/2014	501	17	N/A	20	N/A
5/25/2014	477	19	N/A	21	N/A
2/23/2014	463	19	N/A	22	N/A
11/24/2013	454	18	N/A	23	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: LDE şirketinin kazançlarının önümüzdeki 3 yıl içinde düşmesi öngörülüyor (yılda -40.1% ).

Kazançlar ve Piyasa: LDE şirketinin kazançlarının önümüzdeki 3 yıl içinde düşmesi öngörülüyor (yılda -40.1% ).

Yüksek Büyüme Kazançları: LDE şirketinin kazançlarının önümüzdeki 3 yıl içinde düşmesi öngörülüyor.

Gelir ve Pazar: LDE şirketinin gelirinin (yıllık 7.5% ) German pazarından (yıllık 5.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: LDE şirketinin gelirinin (yıllık 7.5% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: LDE 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Lifecore Biomedical Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Lifecore Biomedical, Inc. Reiterates Financial Guidance for Full Year Fiscal 2025

Lifecore Biomedical, Inc. Provides Earnings Guidance for Full Year Fiscal 2025

Lifecore Biomedical, Inc. Provides Revenue Guidance for Full Year Fiscal 2024

Landec Corporation Reiterates Revenue Guidance for the Full Year Fiscal 2023

Landec Corporation Provides Revenue Guidance for the Full Year Fiscal 2023

Landec Corporation Reiterates Consolidated Earnings Guidance for the Fiscal Year 2022

Recent updates

Investor sentiment improves as stock rises 17%

Lifecore Biomedical, Inc. Appoints Jackie Klecker as Executive Vice President, Quality and Development Services

Lifecore Biomedical, Inc. announced that it has received $24.307978 million in funding

Lifecore Biomedical, Inc. Reiterates Financial Guidance for Full Year Fiscal 2025

Lifecore Biomedical Announces High-Speed, Multi-Purpose 5-Head Isolator Filler Is Gmp-Ready and Operational

Lifecore Biomedical, Inc. Appoints Brikkelle Thompson as Senior Vice President of Human Resources

Lifecore Biomedical Announces Chief Financial Officer Transition

Lifecore Biomedical, Inc. Provides Earnings Guidance for Full Year Fiscal 2025

Lifecore Biomedical, Inc. announced delayed annual 10-K filing

Third quarter 2024 earnings released: EPS: US$0.48 (vs US$0.51 loss in 3Q 2023)

Gainey Mckenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Lifecore Biomedical, Inc

Lifecore Biomedical, Inc. Announces Board Changes

Lifecore Biomedical Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Requirements for Continued Listing Under Nasdaq Listing Rule 5620(a)

Lifecore Biomedical, Inc., Annual General Meeting, Aug 15, 2024

Lifecore Biomedical, Inc. announced delayed 10-Q filing

Lifecore Biomedical, Inc. Provides Revenue Guidance for Full Year Fiscal 2024

Lifecore Biomedical, Inc. Announces Chief Executive Officer Changes, Effective May 20, 2024

Lifecore Biomedical Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal

Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report

Lifecore Biomedical, Inc. announced delayed 10-Q filing

Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Annual Report

Lifecore Biomedical, Inc. announced delayed 10-Q filing

Lifecore Biomedical Receives Notice from Nasdaq Regarding Delayed Quarterly Report

Lifecore Biomedical, Inc.(NasdaqGS:LFCR) dropped from Russell 2000 Dynamic Index

Third quarter 2023 earnings released: US$0.51 loss per share (vs US$0.24 loss in 3Q 2022)

High number of new directors

Lifecore Biomedical Receives A Notification Letter from Nasdaq Due to Delay in Filing Its Quarterly Report on Form 10-Q for the Period Ended November 27, 2022

Lifecore Biomedical, Inc. announced that it has received $38.75 million in funding from Legion Partners Asset Management, LLC, 22NW, LP, 325 Capital, LLC, Cove Street Partners, Wynnefield Capital, Inc.

Lifecore Biomedical, Inc. announced delayed 10-Q filing

Lifecore Biomedical, Inc. announced that it has received $5.003136 million in funding

Landec Corporation Reiterates Revenue Guidance for the Full Year Fiscal 2023

Landec Corporation to Report Q1, 2023 Results on Oct 06, 2022

Landec Corporation, Annual General Meeting, Nov 01, 2022

Landec Corp. Receives Notice from Nasdaq Regarding Delayed Annual Report

Landec Corporation announced delayed annual 10-K filing

Full year 2022 earnings released: US$1.56 loss per share (vs US$1.12 loss in FY 2021)

Landec Corporation Provides Revenue Guidance for the Full Year Fiscal 2023

Landec Corporation(NasdaqGS:LNDC) dropped from Russell 2000 Value-Defensive Index

High number of new directors

Third quarter 2022 earnings released: US$0.24 loss per share (vs US$0.19 loss in 3Q 2021)

Landec Corporation Reiterates Consolidated Earnings Guidance for the Fiscal Year 2022

High number of new directors

Independent Director recently bought €91k worth of stock

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Landec Corporation Provides Consolidated Revenue Guidance for Full Year Fiscal 2022

Landec Corporation Provides Earnings Guidance for the First Half, Second Half and Full Year of Fiscal 2022

First quarter 2022 earnings released: US$322 loss per share (vs US$0.38 loss in 1Q 2021)

Full year 2021 earnings released: US$1.12 loss per share (vs US$1.31 loss in FY 2020)

High number of new directors

President of Lifecore recently bought €89k worth of stock

Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.40 loss in 3Q 2020)

Landec Corporation Provides Revenue Guidance for the Full Fiscal Year 2021

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin